Skip to main content Accessibility help
×
Home

Exploring psychological symptoms and associated factors in patients receiving medication-assisted treatment for opioid-use disorder

  • Tea Rosic (a1), Andrew Worster (a2), Lehana Thabane (a3), David C. Marsh (a4) and Zainab Samaan (a5)...

Abstract

Background

Patients receiving treatment for opioid-use disorder (OUD) may experience psychological symptoms without meeting full criteria for psychiatric disorders. The impact of these symptoms on treatment outcomes is unclear.

Aims

To determine the prevalence of psychological symptoms in a cohort of individuals receiving medication-assisted treatment for OUD and explore their association with patient characteristics and outcomes in treatment.

Method

Data were collected from 2788 participants receiving ongoing treatment for OUD recruited in two Canadian prospective cohort studies. The Maudsley Addiction Profile psychological symptoms subscale was administered to all participants via face-to-face interviews. A subset of participants (n = 666) also received assessment for psychiatric disorders with the Mini International Neuropsychiatric Interview. We used linear regression analysis to explore factors associated with psychological symptom score.

Results

The mean psychological symptom score was 12.6/40 (s.d. = 9.2). Participants with psychiatric comorbidity had higher scores than those without (mean 16.8 v. 8.6, P<0.001) and 31% of those with psychiatric comorbidity reported suicidal ideation. Higher psychological symptom score was associated with female gender (B = 1.59, 95% CI 0.92–2.25, P<0.001), antidepressant prescription (B = 4.35, 95% CI 3.61–5.09, P<0.001), percentage of opioid-positive urine screens (B = 0.02, 95% CI 0.01–0.03, P<0.001), and use of non-opioid substances (B = 1.92, 95% CI 0.89–2.95, P<0.001). Marriage and employment were associated with lower psychological symptoms.

Conclusions

Psychological symptoms are associated with treatment outcomes in this population and the prevalence of suicidal ideation is an area of concern. Our findings highlight the ongoing need to optimise integrated mental health and addictions services for patients with OUD.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Exploring psychological symptoms and associated factors in patients receiving medication-assisted treatment for opioid-use disorder
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Exploring psychological symptoms and associated factors in patients receiving medication-assisted treatment for opioid-use disorder
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Exploring psychological symptoms and associated factors in patients receiving medication-assisted treatment for opioid-use disorder
      Available formats
      ×

Copyright

This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

Hide All
1Organisation for Economic Co-operation and Development. Addressing Problematic Opioid Use in OECD Countries. OECD Health Policy Studies, OECD Publishing, 2019.
2Mattick, RP, Breen, C, Kimber, J, Davoli, M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; 8: CD002209.
3Nielsen, S, Larance, B, Degenhardt, L, Gowing, L, Kehler, C, Lintzeris, N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev 2016; 9: CD011117.
4Mancino, M, Curran, G, Han, C, Allee, E, Humphreys, K, Booth, BM. Predictors of attrition from a national sample of methadone maintenance patients. Am J Drug Alcohol Abuse 2010; 36: 155–60.
5Rosic, T, Naji, L, Bawor, M, Dennis, BB, Plater, C, Marsh, DC, et al. The impact of comorbid psychiatric disorders on methadone maintenance treatment in opioid use disorder: a prospective cohort study. Neuropsychiatr Dis Treat 2017; 13: 1399–408.
6Rounsaville, BJ, Weissman, MM, Crits-Christoph, K, Wilber, C, Kleber, H. Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome. Arch Gen Psychiatry 1982; 39: 151–6.
7Peles, E, Schreiber, S, Adelson, M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend 2006; 82: 211–7.
8Huang, CL, Lee, CW. Factors associated with mortality among heroin users after seeking treatment with methadone: a population-based cohort study in Taiwan. J Subst Abuse Treat 2013; 44: 295300.
9Regier, DA, Farmer, ME, Rae, DS, Locke, BZ, Keith, SJ, Judd, LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511–8.
10Kessler, RC, Nelson, CB, McGonagle, KA, Edlund, MJ, Frank, RG, Leaf, PJ. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 1996; 66: 1731.
11Kadden, RM, Kranzler, HR, Rounsaville, BS. Validity of the distinction between substance-induced and independent depression and anxiety disorders. Am J Addict 1995; 4: 107117.
12Schuckit, MA. Comorbidity between substance use disorders and psychiatric conditions. Addiction 2006; 101 (Suppl 1): 7688.
13Quello, SB, Brady, KT, Sonne, SC. Mood disorders and substance use disorder: a complex comorbidity. Sci Pract Perspect 2005; 3: 1321.
14Dennis, BB, Roshanov, PS, Naji, L, Bawor, M, Paul, J, Plater, C, et al. Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria. Trials 2015; 16: 475.
15Davidson, L, White, W. The concept of recovery as an organizing principle for integrating mental health and addiction services. J Behav Health Serv Res 2007; 34: 109–20.
16Samaan, Z, Bawor, M, Dennis, BB, Plater, C, Varenbut, M, Daiter, J, et al. Genetic influence on methadone treatment outcomes in patients undergoing methadone maintenance treatment for opioid addiction: a pilot study. Neuropsychiatr Dis Treat 2014; 10: 1503–8.
17American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, revised) (DSM-IV-TR). American Psychiatric Publishing, 2000.
18American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th edn) (DSM-5). American Psychiatric Publishing, 2013.
19Elm, Ev, Altman, DG, Egger, M, Pocock, SJ, Gøtzsche, PC, Vandenbroucke, JP, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335: 806–8.
20Marsden, J, Gossop, M, Stewart, D, Best, D, Farrell, M, Lehmann, P, et al. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction 1998; 93: 1857–68.
21Derogatis, LR. BSI Brief Symptom Inventory: Administration, Scoring, and Procedures Manual (4th edn). National Computer Systems, 1993.
22Derogatis, LR. SCL-90-R: Administration, Scoring of Procedures Manual-II for the Revised Version and Other Instruments of the Psychopathology Rating Scale Series. Clinical Psychometric Research Incorporated, 1992.
23Harris, PA, Taylor, R, Thielke, R, Payne, J, Gonzalez, N, Conde, JG. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377–81.
24Harris, PA, Taylor, R, Minor, BL, Elliott, V, Fernandez, M, O'Neal, L, et al. The REDCap consortium: building an international community of software partners. J Biomed Inform 2019; 95: 103208.
25Sheehan, DV, Lecrubier, Y, Sheehan, KH, Amorim, P, Janavs, J, Weiller, E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (suppl 20): 2233. quiz 34–57.
26NOVX Systems. Inventor iMDxTM. NOVX Systems, no date (http://www.novxsystems.com/patientVu-addiction.html).
27StataCorp. Stata Statistical Software: Release 15. StataCorp, 2017.
28Lyness, JM, Cox, C, Curry, J, Conwell, Y, King, DA, Caine, ED. Older age and the underreporting of depressive symptoms. J Am Geriatr Soc 1995; 43: 216–21.
29Eaton, NR, Keyes, KM, Krueger, RF, Balsis, S, Skodol, AE, Markon, KE, et al. An invariant dimensional liability model of gender differences in mental disorder prevalence: evidence from a national sample. J Abnorm Psychol 2012; 121: 282–8.
30Simon, RW. Revisiting the relationships among gender, marital status, and mental health. AJS 2002; 107: 1065–96.
31Paul, KI, Moser, K. Unemployment impairs mental health: meta-analyses. J Vocat Beh 2009; 74: 264–82.
32Peduzzi, P, Concato, J, Kemper, E, Holford, TR, Feinstein, AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49: 1373–9.
33Fingleton, N, Matheson, C, Jaffray, M. Changes in mental health during opiate replacement therapy: a systematic review. Drugs Educ Prev Policy 2015; 22: 118.
34Collins, R, Boggs, B, Taggart, N, Kelly, M, Drillington, A, Swanton, I, et al. Efficacy of treatment in an opioid –dependent population group using the Maudsley Addiction Profile (MAP) tool. Ulster Med J 2009; 78: 21–5.
35Comiskey, CM. A 3year national longitudinal study comparing drug treatment outcomes for opioid users with and without children in their custodial care at intake. J Subst Abuse Treat 2013; 44: 90–6.
36Comiskey, CM, Cox, G. Analysis of the impact of treatment setting on outcomes from methadone treatment. J Subst Abuse Treat 2010; 39: 195201.
37Robertson, JR, Raab, GM, Bruce, M, McKenzie, JS, Storkey, HR, Salter, A. Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: a randomized controlled trial. Addiction 2006; 101: 1752–9.
38Hallgren, KA, Ries, RK, Atkins, DC, Bumgardner, K, Roy-Byrne, P. Prediction of suicide ideation and attempt among substance-using patients in primary care. J Am Board Fam Med 2017; 30: 150–60.
39Bohnert, AS, Ilgen, MA. Understanding links among opioid use, overdose, and suicide. NEJM 2019; 380: 71–9.
40Rockett, IRH, Caine, ED, Connery, HS, D'Onofrio, G, Gunnell, DJ, Miller, TR, et al. Discerning suicide in drug intoxication deaths: paucity and primacy of suicide notes and psychiatric history. PLoS One 2018; 13: e0190200.
41Barber, CW, Miller, MJ. Reducing a suicidal person's access to lethal means of suicide: a research agenda. Am J Prev Med 2014; 47 (Suppl): 264–72.

Keywords

Exploring psychological symptoms and associated factors in patients receiving medication-assisted treatment for opioid-use disorder

  • Tea Rosic (a1), Andrew Worster (a2), Lehana Thabane (a3), David C. Marsh (a4) and Zainab Samaan (a5)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Exploring psychological symptoms and associated factors in patients receiving medication-assisted treatment for opioid-use disorder

  • Tea Rosic (a1), Andrew Worster (a2), Lehana Thabane (a3), David C. Marsh (a4) and Zainab Samaan (a5)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *